Mariam E Sunny

1 month ago | risingnepaldaily.com | Mariam E Sunny |Kamal Choudhury

By Mariam E Sunny and Kamal Choudhury, March 24: Tuberculosis (TB) infections among children in the European region rose 10% in 2023, indicating ongoing transmission and the need for immediate public health measures to control the spread, the World Health Organization said on Monday. WHO's European region, which comprises 53 countries in Europe and Central Asia, reported more than 7,500 cases among children under 15 years of age in 2023, an increase of over 650 cases compared to 2022.

Mar 8, 2024 | reuters.com | Mariam E Sunny

March 8 (Reuters) - Amylyx Pharmaceuticals (AMLX.O), opens new tab is considering withdrawing its treatment for amyotrophic lateral sclerosis from the market after the drug failed to slow disease progression in a late-stage trial, sending its shares crashing 85% on Friday. The company said it would stop promotions of the drug and decide on its future in coming weeks after discussions with regulators. Meanwhile, the drug will be available at this time.

Mar 7, 2024 | reuters.com | Mariam E Sunny

The headquarters of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009/ File Photo March 7 (Reuters) - The U.S. Food and Drug Administration has granted accelerated approval for the expanded use of BeiGene's (6160.HK), opens new tab combination drug to treat certain patients with a type of blood cancer, the health regulator said on Thursday.

Mar 3, 2024 | today.westlaw.com | Shinjini Ganguli |Anil D'Silva |Mariam E Sunny

(Reuters) -Walgreens Boots Alliance's CEO rejected a media report, saying the company does not plan to sell specialty pharmacy unit Shields Health Solutions at least for nowThe pharmacy chain is instead looking for ways to drive "the most value" for...

Feb 27, 2024 | jp.reuters.com | Mariam E Sunny |Bhanvi Satija

[２７日 ロイター] - 米バイオ医薬品企業バイキング・セラピューティクス(VKTX.O), opens new tabは２７日、開発中の注射タイプの肥満症治療薬「ＶＫ２７３５」が、中期臨床試験で被験者の体重を平均１５％弱減らす効果を示したと発表した。 これを受け同社の株価は１２０％上昇した。 肥満症治療薬市場は現在、イーライリリー(LLY.N), opens new tabの「ゼップバウンド」とノボノルディスク(NOVOb.CO), opens new tabの「ウゴービ」が２強として支配的地位を築いている。ただトゥルーイスト・セキュリティーズのアナリスト、ジューン・リー氏は「（バイキングの新薬が）イーライリリーとノボノルディスクの牙城に割って入れる可能性がある」と述べた。 ＶＫ２７３５は、ゼップバウンドやウゴービと同じＧＬＰ－１受容体作動薬と呼ばれるカテゴリーに属する。 臨床試験の好結果は投資家だけでなく、Ｍ＆Ａ（合併・買収）などの面で大手製薬各社にとってもバイキングへの注目度が高まっているのは間違いない。...